In vivo effects of phenylbutazone on inflammation and cartilage-derived biomarkers in equine joints with acute synovitis.
Authors: de Grauw J C, van Loon J P A M, van de Lest C H A, Brunott A, van Weeren P R
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Phenylbutazone's Limited Effects on Cartilage Turnover in Acute Joint Inflammation Phenylbutazone remains a mainstay of equine orthopaedic management despite limited understanding of how it influences both inflammatory processes and cartilage metabolism within affected joints. De Grauw and colleagues used a crossover design in seven ponies to evaluate PBZ's effects on synovitis induced by lipopolysaccharide injection into the middle carpal joint, measuring inflammatory markers (substance P, general MMP activity), cartilage degradation (glycosaminoglycans, C2C collagen cleavage) and synthesis (CPII) in synovial fluid over 28 days. Whilst PBZ proved clinically effective at managing the acute inflammatory response, it failed to suppress the catabolic markers typically associated with cartilage breakdown—substance P and MMP activity remained unchanged, as did glycosaminoglycan and C2C concentrations—although CPII synthesis markers were significantly reduced at 24 and 168 hours. The findings suggest that PBZ's therapeutic benefit in acute synovitis operates primarily through anti-inflammatory mechanisms affecting pain and clinical signs rather than through protection of cartilage metabolism; practitioners should therefore consider complementary approaches to mitigate cartilage turnover changes, particularly in cases where extended anti-inflammatory cover may be warranted.
Read the full abstract on PubMed
Practical Takeaways
- •Phenylbutazone controls clinical signs of acute joint inflammation but does not prevent cartilage catabolism at the biochemical level
- •The reduction in collagen synthesis (CPII) with phenylbutazone suggests anti-anabolic effects on cartilage repair that deserve clinical consideration in recovery management
- •Relying solely on phenylbutazone for acute synovitis may need supplementation with other strategies to protect cartilage turnover during acute inflammatory episodes
Key Findings
- •Phenylbutazone did not significantly reduce substance P or general MMP activity in synovial fluid despite clinical effectiveness
- •Phenylbutazone did not reduce cartilage degradation markers (GAG, C2C) at any time point during acute LPS-induced synovitis
- •Phenylbutazone significantly reduced collagen II synthesis marker (CPII) at 24 and 168 hours post-treatment
- •LPS injection produced marked transient synovitis without visible cartilage damage on arthroscopic examination